Advertisement
open access
Medical Conferences

Medical Conferences

  • Conference Reports
    • 2023 Medicom Conference Planning
  • Conference Proceedings
  • Disease Areas
  • Other Medical News
  • Media
    • Podcast
    • Video
    • Education
  • About
    • Conference Proceedings
    • Vacancies

Tag: Adalimumab

AxSpA: Adalimumab biosimilar equally effective as IL-17 inhibitor in hindering radiographic progression

Presented By
Prof. Xenofon Baraliakos, Rheumazentrum Ruhrgebiet, Germany
Trial
Phase 3, SURPASS
Conference
EULAR 2023

31 July, 2023 06:22

Anti-TNF withdrawal may be a safe option in stable IBD

Presented By
Prof. María Chaparro Sánchez , Hospital Universitario de La Princesa, Spain
Trial
Phase 4, EXIT
Conference
ECCO 2023

4 May, 2023 16:12

Intensified drug therapy leads to better stricture morphology in CD

Presented By
Dr Julien Schulberg , St Vincent’s Hospital Melbourne, Australia
Trial
STRIDENT
Conference
ECCO 2023

4 May, 2023 16:03

Dose-interval of adalimumab might be prolonged in CD patients in stable remission

Presented By
Dr Reinier van Linschoten , Franciscus Gasthuis en Vlietland, the Netherlands
Trial
Phase 4, LADI
Conference
UEGW 2022

1 December, 2022 17:01

High rate of non- or partial responders jeopardises therapeutic success in HS

Presented By
Dr Hayley Wallinger, Adelphi Real World, UK
Conference
EADV 2022

5 November, 2022 11:15

Greater PASI reductions lead to less impairment in social and sexual life

Trial
Phase 3, VOYAGE 1, VOYAGE 2
Conference
SPIN 2022

26 August, 2022 10:32

How to treat enthesitis in 2022

Presented By
Prof. Dennis McGonagle, University of Leeds, United Kingdom
Trial
Phase 3, SEAM-PsA, EXCEED, SPIRIT-H2H
Conference
EULAR 2022

21 July, 2022 17:42

Dermatology diseases need the highest doses of biologics

Presented By
Dr Charlotte Greif, Beth Israel Deaconess Medical Center, USA
Conference
AAD 2022

17 May, 2022 12:24

Early biologic therapy induces larger effect than delayed treatment in Crohn’s disease

Presented By
Prof. Shomron Ben-Horin, Tel-Aviv University, Israel
Conference
ECCO 2022

12 April, 2022 17:21

Anti-TNFs versus vedolizumab and ustekinumab in Crohn’s disease

Presented By
Dr Neeraj Narula, McMaster University, Canada
Conference
ECCO 2022

12 April, 2022 16:46

Upadacitinib appears to be an efficacious therapy for moderately-to-severely ulcerative colitis

Presented By
Prof. Remo Panaccione , University of Calgary, Canada
Conference
ECCO 2022

12 April, 2022 16:44

Tapering biologics: No alarming signs of increased anti-drug antibodies

Presented By
Dr Juul van den Reek , Radboudumc, the Netherlands
Trial
Phase 4, CONDOR
Conference
PFGC 2021

2 February, 2022 14:43

HLA-C*06:02-positive patients on ustekinumab show higher drug survival in a real-world scenario

Presented By
Dr Oras Alabas, University of Manchester, UK
Conference
PFGC 2021

2 February, 2022 14:05

Protective factors identified against anti-drug antibody formation to adalimumab in psoriasis

Presented By
Dr Teresa Tsakok, King’s College London, UK
Conference
PFGC 2021

2 February, 2022 13:37

PFGC 2021 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Conference
PFGC 2021

22 December, 2021 08:12

Potential role of inflammation in cardiovascular comorbidity

Presented By
Dr Alexander Egeberg, Herlev and Gentofte Hospital, Denmark
Trial
Phase 3, CANTOS, CIRT
Conference
WPPAC 2021

17 September, 2021 11:13

ECCO 2021 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Conference
ECCO 2021

10 August, 2021 08:17

ABBV-3373: A potential new therapeutic agent for RA

Presented By
Dr Frank Buttgereit, Charité University Medicine, Germany
Conference
EULAR 2021

2 August, 2021 19:05

Similar efficacy of ustekinumab and adalimumab for moderate-to-severe CD

Presented By
Dr Peter Irving, Guy’s and St. Thomas’ Hospital, UK
Trial
SEAVUE
Conference
ECCO 2021

2 July, 2021 23:45

Risk of hospitalisation and surgery linked to IBD biological

Presented By
Dr Camilla Bjørn Jensen, Frederiksberg Hospital
Conference
ECCO 2021

2 July, 2021 20:20

Obesity increases the risk of immunogenicity to adalimumab in IBD

Presented By
Dr Remi Mahmoud, University Medical Centre Utrecht, the Netherlands
Conference
ECCO 2021

2 July, 2021 14:24

No elevated risk for influenza AE in tofacitinib-treated RA patients

Conference
ACR 2020

18 January, 2021 10:42

Adalimumab added to methotrexate yields better results in PsA than methotrexate escalatio

Presented By
Dr Laura Coates, Oxford University, United Kingdom
Trial
Phase 4, CONTROL
Conference
EULAR 2020

14 August, 2020 14:09

Upadacitinib provides fast onset of improvement in psoriatic arthritis

Presented By
Prof. Iain McInnes, University of Glasgow, Scotland
Trial
SELECT-PsA-1
Conference
EULAR 2020

14 August, 2020 14:02

Secukinumab monotherapy as efficient as adalimumab

Presented By
Prof. Iain McInnes, University of Glasgow, United Kingdom
Trial
Phase 3, EXCEED
Conference
EULAR 2020

14 August, 2020 13:11

Biologics in HS – a growing armamentarium

Presented By
Prof. Joslyn Kirby, Penn State University, USA
Trial
PIONEER
Conference
AAD 2020

6 August, 2020 12:48

Biologic psoriasis treatment to lower cardiovascular risk?

Presented By
Prof. Joel Gelfand, University of Pennsylvania, USA
Conference
AAD 2020

6 August, 2020 08:01

Effects of vedolizumab versus adalimumab on QoL

Presented By
Dr E.V. Loftus, Mayo Clinic, USA
Trial
VARSITY
Conference
ECCO 2020

14 April, 2020 15:39

Vedolizumab and anti-TNF therapies: a real-world comparison

Presented By
Dr G. Mantzaris , Evangelismos Hospital, Greece
Trial
EVOLVE
Conference
ECCO 2020

14 April, 2020 15:35

Vedolizumab, adalimumab, and golimumab compared

Presented By
Dr F.S. Macaluso & Dr A. Casanotti
Conference
ECCO 2020

14 April, 2020 15:32

High versus standard adalimumab in active UC

Presented By
Prof. J. Colombel, Icahn School of Medicine at Mount Sinai, USA
Trial
Phase 3, SERENE-UC
Conference
ECCO 2020

14 April, 2020 14:47

TNFi for RA during pregnancy – to stop or not to stop?

Presented By
Dr Isabell Haase, Heinrich-Heine University Düsseldorf, Germany
Conference
ACR 2019

4 February, 2020 10:16

Biologics: increasingly used in paediatric dermatology

Presented By
Prof. Marieke Seyger, Radboud University Nijmegen, the Netherlands
Conference
EADV 2019

9 December, 2019 15:16

ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker

Presented By
Prof. Diamant Thaçi, University of Lübeck, Germany
Trial
ESPRIT
Conference
EADV 2019

9 October, 2019 19:23

Switching upadacitinib and adalimumab is beneficial in refractory RA

Trial
Phase 3, SELECT-COMPARE
Conference
EULAR 2019

4 September, 2019 17:54

Efficacy and safety of ixekizumab versus adalimumab in patients with PsA

Presented By
Dr Roy Fleischmann, University of Texas Southwestern Medical Center, Dallas, USA
Conference
EULAR 2019

4 September, 2019 11:20

Switch to sarilumab from adalimumab is efficacious and safe

Presented By
Dr Gerd Burmester, Free University and Humboldt University of Berlin, Germany
Trial
MONARCH
Conference
EULAR 2019

4 September, 2019 10:07

Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity

Presented By
Dr Gayle van der Kraaij, Amsterdam UMC, the Netherlands
Conference
SPIN 2019

21 June, 2019 20:57

ABP501 biosimilar for adalimumab: What you need to know

Presented By
Prof. Brian Kirby, St Vincent's Hospital, Dublin, Ireland
Conference
SPIN 2019

21 June, 2019 17:24

Vedolizumab superior to adalimumab in ulcerative colitis

Presented By
Dr Stefan Schreiber, University-Hospital Schleswig-Holstein, Germany
Trial
Phase 3, VARSITY
Conference
ECCO 2019

9 May, 2019 22:57

Proactive adalimumab trough measurements

Presented By
Dr Amit Assa, Schneider Children’s Hospital, Israel
Conference
ECCO 2019

9 May, 2019 10:20

Plaque psoriasis – Efficacy of guselkumab

Trial
Phase 3, VOYAGE 1, VOYAGE 2
Conference
AAD 2019

19 April, 2019 20:06

Biologic drug levels and infection risk, and clinical effectiveness of sarilumab

Trial
TARGET
Conference
EULAR 2018

24 August, 2018 19:30

Confirmation of long-term safety profile adalimumab across indications

Presented By
Prof. Gerd Burmester, Charité University Hospital, Free University and Humboldt University of Berlin, Germany
Conference
EULAR 2018

24 August, 2018 18:39

Combining new drugs with different mechanisms

Trial
EXPLORER
Conference
ECCO 2018

28 May, 2018 23:31

Long-term safety profile of adalimumab

Trial
ULTRA 1, ULTRA 2
Conference
ECCO 2018

28 May, 2018 22:07

Targeting early disease: lessons from rheumatoid arthritis

Trial
OPTIMA
Conference
ECCO 2018

28 May, 2018 19:27

Targeting early disease: lessons from rheumatoid arthritis


28 May, 2018 19:19
site created by:   

© 2023 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy